O
1.62
0.04 (2.53%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Opko Health, Inc. | Bearish | Bearish |
Stockmoo Score
1.3
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 3.00 (Piper Sandler, 85.19%) | Buy |
| Median | 2.63 (62.35%) | |
| Low | 2.25 (Barrington Research, 38.89%) | Buy |
| Average | 2.63 (62.35%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.48 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 08 Aug 2024 | 2.25 (38.89%) | Buy | 1.43 |
| Piper Sandler | 18 Jul 2024 | 3.00 (85.19%) | Buy | 1.52 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Aug 2024 | Announcement | OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results |
| 01 Aug 2024 | Announcement | OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 |
| 18 Jul 2024 | Announcement | OPKO Health Announces $100 Million Share Repurchase Program |
| 17 Jul 2024 | Announcement | OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments |
| 02 Jul 2024 | Announcement | NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |